Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Cash from Financing Activities (2016 - 2025)

Kiora Pharmaceuticals' Cash from Financing Activities history spans 10 years, with the latest figure at $296.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities changed N/A year-over-year to $296.0; the TTM value through Dec 2025 reached $265655.0, down 98.29%, while the annual FY2025 figure was $265655.0, 98.29% down from the prior year.
  • Cash from Financing Activities reached $296.0 in Q4 2025 per KPRX's latest filing, down from $265359.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $15.2 million in Q1 2024 to a low of -$486421.0 in Q4 2023.
  • Average Cash from Financing Activities over 4 years is $3.9 million, with a median of $389267.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: plummeted 197.38% in 2021, then surged 2871.23% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at -$212282.0 in 2021, then plummeted by 129.14% to -$486421.0 in 2023, then soared by 151.5% to $250523.0 in 2024, then crashed by 99.88% to $296.0 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Cash from Financing Activities are $296.0 (Q4 2025), $265359.0 (Q2 2025), and $250523.0 (Q2 2024).